Microglia Share Synuclein Aggregates with Each Other Via Nanotubes
When microglia get overwhelmed by α-synuclein, they pass off aggregates to unburdened neighbors. which pass fresh mitochondria back in exchange.
6390 RESULTS
Sort By:
When microglia get overwhelmed by α-synuclein, they pass off aggregates to unburdened neighbors. which pass fresh mitochondria back in exchange.
The sandwich immunoassay recognizes small soluble oligomers in both cerebrospinal fluid and plasma with high sensitivity and specificity.
The APOE3-Jacksonville variant generates a protein whose greater lipid-hauling capacity renders it less prone to self-aggregate. This boosted phospholipid trafficking and reduced the number of plaques and downstream damage.
High-resolution structures of tau fibrils from a variety of tauopathies reveal distinct folds—and important similarities—among syndromes. The folds facilitate a classification of tauopathies.
In a collaborative tour de force, scientists for the first time compared eight Aβ assays in the same plasma samples. Mass-spectrometry assays more accurately picked up brain amyloid than did most immunoassays, but one fully automated immunoassay was on par.
That long-sought astrocyte toxicity factor? Scientists say it's certain long-chain fatty acids. No, not the ones we get from our diet.
Cognitively intact 70-year-old people carrying APOE4 recalled objects and their locations slightly better than did noncarriers. The advantage persisted even among people who had amyloid plaques.
Bumetanide normalizes molecular signatures linked to the AD risk allele. People taking the medicine may be less likely to develop Alzheimer’s.
A new study reports that activated microglia soak up glucose, and may be responsible for the elevated FDG PET signal seen in early Alzheimer's disease. Mouse microglia used 28 times more FDG than did neurons.
The AD risk allele steers microglia toward an inflammatory state long before plaques or tangles emerge.
An analysis suggests most Medicare beneficiaries have medical conditions that would disqualify them from using the new drug; this may further limit its clinical rollout.
In a tiny Phase 3 trial of the ASO tofersen, a neurodegeneration marker changed in the right direction. Trends on other endpoints favored drug. Still, the trial was negative. Next steps for tofersen remain up in the air.
The academy elected 90 new members. Five are well-known for their contributions to the field of neurodegenerative diseases.
The SARS-CoV2 spike and other viral glycoproteins promote the transmission of proteopathic seeds carried by extracellular vesicles.
In tau knockout mice, excitatory neurons fire less; inhibitory neurons fire more. Could this dampen hyperexcitability in conditions such as Alzheimer’s?
No filters selected